{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:52:17Z","timestamp":1789012337135,"version":"build-2803163510"},"reference-count":54,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with multiple myeloma (MM) have a diminished immune response to coronavirus disease 2019 (COVID-19) vaccines. Risk factors for an impaired immune response are yet to be determined. We aimed to summarize the COVID-19 vaccine immunogenicity and to identify factors that influence the humoral immune response in patients with MM. Two reviewers independently conducted a literature search in MEDLINE, Embase, ISI Web of Science, Cochrane library, and Clinicaltrials.gov from existence until 24 May 24 2022. (PROSPERO: CRD42021277005). A total of 15 studies were included in the systematic review and 5 were included in the meta-analysis. The average rate (range) of positive functional T-lymphocyte response was 44.2% (34.2%-48.5%) after 2 doses of messenger RNA (mRNA) COVID-19 vaccines. The average antispike antibody response rates (range) were 42.7% (20.8%-88.5%) and 78.2% (55.8%-94.2%) after 1 and 2 doses of mRNA COVID-19 vaccines, respectively. The average neutralizing antibody response rates (range) were 25% (1 study) and 62.7% (53.3%-68.6%) after 1 and 2 doses of mRNA COVID-19 vaccines, respectively. Patients with high-risk cytogenetics or receiving anti-CD38 therapy were less likely to have a humoral immune response with pooled odds ratios of 0.36 (95% confidence interval [95% CI], 0.18, 0.69), I2\u00a0= 0% and 0.42 (95% CI, 0.22, 0.79), I2\u00a0=\u00a014%, respectively. Patients who were not on active MM treatment were more likely to respond with pooled odds ratio of 2.42 (95% CI, 1.10, 5.33), I2\u00a0= 7%. Patients with MM had low rates of humoral and cellular immune responses to the mRNA COVID-19 vaccines. Further studies are needed to determine the optimal doses of vaccines and evaluate the use of monoclonal antibodies for pre-exposure prophylaxis in this population.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008530","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T16:36:36Z","timestamp":1671554196000},"page":"6198-6207","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9474-637X","authenticated-orcid":false,"given":"Nipat","family":"Chuleerarux","sequence":"first","affiliation":[{"name":"1Department of Medicine, Jackson Memorial Hospital, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-143X","authenticated-orcid":false,"given":"Kasama","family":"Manothummetha","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6257-0867","authenticated-orcid":false,"given":"Chatphatai","family":"Moonla","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3662-4136","authenticated-orcid":false,"given":"Anawin","family":"Sanguankeo","sequence":"additional","affiliation":[{"name":"4Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4381-0049","authenticated-orcid":false,"given":"Olivia S.","family":"Kates","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2224-6856","authenticated-orcid":false,"given":"Nattiya","family":"Hirankarn","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0656-5120","authenticated-orcid":false,"given":"Kasidis","family":"Phongkhun","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-5387","authenticated-orcid":false,"given":"Jaedvara","family":"Thanakitcharu","sequence":"additional","affiliation":[{"name":"6Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-3056","authenticated-orcid":false,"given":"Surachai","family":"Leksuwankun","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9544-7096","authenticated-orcid":false,"given":"Tanaporn","family":"Meejun","sequence":"additional","affiliation":[{"name":"7Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-1062","authenticated-orcid":false,"given":"Achitpol","family":"Thongkam","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6590-1729","authenticated-orcid":false,"given":"Thanuthong","family":"Mongkolkaew","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5326-9551","authenticated-orcid":false,"given":"M. Veronica","family":"Dioverti","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-6339","authenticated-orcid":false,"given":"Pattama","family":"Torvorapanit","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1889-7122","authenticated-orcid":false,"given":"Nattapong","family":"Langsiri","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5055-6830","authenticated-orcid":false,"given":"Navaporn","family":"Worasilchai","sequence":"additional","affiliation":[{"name":"8Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1622-1209","authenticated-orcid":false,"given":"Rongpong","family":"Plongla","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9761-1670","authenticated-orcid":false,"given":"Ariya","family":"Chindamporn","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2484-6137","authenticated-orcid":false,"given":"Shilpa","family":"Gopinath","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0245-2954","authenticated-orcid":false,"given":"Pitchaphon","family":"Nissaisorakarn","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6678-5993","authenticated-orcid":false,"given":"Tany","family":"Thaniyavarn","sequence":"additional","affiliation":[{"name":"10Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"11Department of Medicine, Veterans Affairs Medical Center, West Roxbury, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-1120","authenticated-orcid":false,"given":"Saman","family":"Nematollahi","sequence":"additional","affiliation":[{"name":"12Department of Medicine, University of Arizona College of Medicine, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0749-7342","authenticated-orcid":false,"given":"Nitipong","family":"Permpalung","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"},{"name":"5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"issue":"10","key":"2023053018341952400_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-020-00372-5","article-title":"Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality","volume":"10","author":"Mart\u00ednez-L\u00f3pez","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"2023053018341952400_bib2","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"issue":"25","key":"2023053018341952400_bib3","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2023053018341952400_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"2023053018341952400_bib5","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2023053018341952400_bib6","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023053018341952400_bib7","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1097\/HS9.0000000000000547","article-title":"SARS-CoV-2 vaccines in patients with multiple myeloma","volume":"5","author":"Gavriatopoulou","year":"2021","journal-title":"Hemasphere"},{"issue":"25","key":"2023053018341952400_bib8","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2023053018341952400_bib9","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023053018341952400_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2023053018341952400_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"2023053018341952400_bib12","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ccell.2021.09.015","article-title":"Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma","volume":"39","author":"Aleman","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"2023053018341952400_bib13","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol"},{"issue":"8","key":"2023053018341952400_bib14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"issue":"12","key":"2023053018341952400_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00597-y","article-title":"SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma","volume":"11","author":"Sgherza","year":"2021","journal-title":"Blood Cancer J"},{"key":"2023053018341952400_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"10","key":"2023053018341952400_bib17","doi-asserted-by":"crossref","first-page":"e1001744","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLoS Med"},{"key":"2023053018341952400_bib18","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2019"},{"issue":"5","key":"2023053018341952400_bib19","first-page":"1148","article-title":"Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation","volume":"37","author":"Patsopoulos","year":"2008","journal-title":"Int\u00a0J\u00a0Epidemiol"},{"issue":"10","key":"2023053018341952400_bib20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"7109","key":"2023053018341952400_bib21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"2023053018341952400_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"2","key":"2023053018341952400_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.17608","article-title":"Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma","volume":"195","author":"Avivi","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2023053018341952400_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01183-2","article-title":"Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls","volume":"14","author":"Bitoun","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2023053018341952400_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.2021013429","article-title":"Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma","volume":"139","author":"En\u00dfle","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2023053018341952400_bib26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.17841","article-title":"Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine","volume":"196","author":"Gavriatopoulou","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2023053018341952400_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-09097-5","article-title":"Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma","volume":"21","author":"Greenberg","year":"2021","journal-title":"BMC Cancer"},{"key":"2023053018341952400_bib28","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood.2021013714","article-title":"Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against Alpha and Delta variants in Multiple Myeloma patients","author":"Henriquez","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2023053018341952400_bib29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjh.17877","article-title":"T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies","volume":"196","author":"Marasco","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2023053018341952400_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2023053018341952400_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.17764","article-title":"COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma","volume":"196","author":"Ramasamy","year":"2022","journal-title":"Br J Haematol"},{"key":"2023053018341952400_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eclinm.2021.101158","article-title":"BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: a prospective cohort study","volume":"41","author":"Rahav","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"12","key":"2023053018341952400_bib33","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41375-021-01354-7","article-title":"Response to mRNA vaccination for COVID-19 among patients with multiple myeloma","volume":"35","author":"Stampfer","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"2023053018341952400_bib34","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjh.18073","article-title":"Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres","volume":"197","author":"\u0160u\u0161ol","year":"2022","journal-title":"Br J Haematol"},{"issue":"26","key":"2023053018341952400_bib35","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose","volume":"137","author":"Terpos","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2023053018341952400_bib36","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood.2021014989","article-title":"Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy","volume":"139","author":"Terpos","year":"2022","journal-title":"Blood"},{"key":"2023053018341952400_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-2-71","article-title":"Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework","volume":"2","author":"Huguet","year":"2013","journal-title":"Syst Rev"},{"issue":"8","key":"2023053018341952400_bib38","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"24","key":"2023053018341952400_bib39","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2023053018341952400_bib40","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/CVI.00021-11","article-title":"Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom\u2019s macroglobulinemia, and monoclonal gammopathy of undetermined significance","volume":"18","author":"Karlsson","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"2023053018341952400_bib41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2023053018341952400_bib42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"key":"2023053018341952400_bib43","unstructured":"Centers for Disease Control and Prevention\n          . COVID-19 vaccines for people who are moderately or severely immunocompromised. Accessed 9 July 2022. https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html."},{"issue":"8","key":"2023053018341952400_bib44","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/leu.2010.128","article-title":"Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma","volume":"24","author":"Kumar","year":"2010","journal-title":"Leukemia"},{"issue":"15","key":"2023053018341952400_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13153800","article-title":"Post-vaccination anti-SARS-CoV-2-antibody response in patients with multiple myeloma correlates with low CD19+ B-lymphocyte count and anti-CD38 treatment","volume":"13","author":"Ghandili","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2023053018341952400_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00530-3","article-title":"The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"issue":"8","key":"2023053018341952400_bib47","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"issue":"11","key":"2023053018341952400_bib48","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol"},{"issue":"11","key":"2023053018341952400_bib49","doi-asserted-by":"crossref","first-page":"e2137575","DOI":"10.1001\/jamanetworkopen.2021.37575","article-title":"Risks of SARS-CoV-2 breakthrough infection and hospitalization in fully vaccinated patients with multiple myeloma","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10325","key":"2023053018341952400_bib50","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0140-6736(22)00090-3","article-title":"Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose","volume":"399","author":"Kuhlmann","year":"2022","journal-title":"Lancet"},{"key":"2023053018341952400_bib51","first-page":"1","article-title":"Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination","volume":"13","author":"Stampfer","year":"2022","journal-title":"Clin Infect Pract"},{"key":"2023053018341952400_bib52","unstructured":"Food and Drug Administration (FDA)\n          . Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals. Accessed 9 July 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure."},{"issue":"23","key":"2023053018341952400_bib53","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab\u2013cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2023053018341952400_bib54","unstructured":"Food and Drug Administration (FDA)\n          . Fact sheet for healthcare providers: emergency use authorization for evusheldtm (tixagevimab co-packaged with cilgavimab). Accessed 9 July 2022. https:\/\/www.fda.gov\/media\/154701\/download."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/24\/6198\/2054342\/blooda_adv-2022-008530-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/24\/6198\/2054342\/blooda_adv-2022-008530-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T18:35:55Z","timestamp":1685471755000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/24\/6198\/486648\/Immunogenicity-of-SARS-CoV-2-vaccines-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":54,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,12,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008530","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]}}}